Affordable Premiums for Seniors Act of 2026
- Sponsor
- Rep. Sewell, Terri A. [D-AL-7]
- Committees
- Ways and Means Committee (primary)
- Last action
- Sep 14, 2026
Bottom line
The bill aims to ensure the ongoing stability and affordability of Medicare Part D prescription drug premiums for seniors by mandating the continuation of an existing demonstration program.
What it actually does
This bill mandates the Secretary of Health and Human Services (HHS) to continue the Medicare Part D Premium Stabilization Demonstration for the years 2027, 2028, and 2029. Furthermore, it requires the Secretary to continue the demonstration indefinitely for 2030 and subsequent years, unless a determination is made that its termination would not result in an increase in premiums for individuals enrolled in Medicare Part D prescription drug plans. The bill also requires HHS to issue revised guidance for the demonstration's operation in 2027 within 30 days of enactment.
Proponents argue
Proponents argue that continuing the Part D Premium Stabilization Demonstration is crucial for protecting seniors from unpredictable and rising prescription drug costs. They contend that this measure provides essential financial predictability for millions of Medicare beneficiaries, ensuring access to necessary medications without undue financial burden. Supporters emphasize that the demonstration has proven effective in its goal of stabilizing premiums and should therefore be made permanent or at least extended indefinitely to maintain these benefits.
Opponents contend
Opponents, particularly those concerned with federal spending and market intervention, might argue that mandating the indefinite continuation of a demonstration program removes necessary oversight and flexibility. They could contend that such a program should be subject to periodic re-evaluation to assess its cost-effectiveness, impact on market competition, and whether it remains the most efficient mechanism for premium stabilization. Critics might also raise concerns about the long-term fiscal implications of permanently embedding a demonstration that could otherwise be allowed to expire or be modified.
The bill is very short and straightforward, allowing for quick comprehension of its core purpose and provisions.
Section 2(a) and 2(b)
Mandatory Continuation of Part D Premium Stabilization Demonstration
This provision requires the Secretary of Health and Human Services to continue the existing Part D Premium Stabilization Demonstration for three additional years (2027, 2028, and 2029) in a manner similar to its operation in 2026. Crucially, it then mandates the demonstration's continuation for 2030 and all subsequent years, effectively making it permanent, unless the Secretary specifically determines that ending it would not lead to higher premiums for Medicare Part D enrollees. This ensures the program's longevity and removes the need for future legislative reauthorization under most circumstances.
Supporters argue
Supporters argue that this provision is vital for providing long-term certainty and affordability for seniors relying on Medicare Part D. They assert that making the demonstration permanent, or nearly so, removes the annual uncertainty and political wrangling over its renewal, allowing beneficiaries to plan their healthcare costs with greater confidence. This stability is seen as a direct benefit to vulnerable populations.
Critics contend
Critics contend that mandating indefinite continuation, especially with a high bar for termination, removes essential accountability and flexibility. They argue that such programs should be regularly reviewed and reauthorized to ensure they remain effective, efficient, and fiscally responsible. Opponents might also suggest that this provision could stifle innovation or market-based solutions if the government is permanently intervening to stabilize premiums, potentially leading to higher costs in the long run.
Tradeoffs
This provision balances the desire for long-term premium stability and predictability for Medicare beneficiaries against concerns about federal spending, the potential for reduced market competition, and the need for periodic program review and adaptation to changing healthcare landscapes.